Terminal2 — Card #31: Multiple Sclerosis (Progressive)

S01 Everyone

What Is It

Definition, mechanism, and the clinical reality of this diagnosis at end of life. What the hospice team needs to understand on day one.

US Prevalence

~1 Million

Most common cause of non-traumatic neurological disability in young adults in the developed world.^[1]

Age at Diagnosis

Median 30 yrs

MS is diagnosed in the prime of life — when patients are building careers, raising children, and planning their futures.^[2]

Progressive Forms

PPMS 15% / SPMS 65%

Together, primary progressive and secondary progressive MS define the hospice population — these are the patients who reach end-stage disease.^[3]

EDSS 8.0+

~10–15%

Bedridden, completely dependent for all self-care — the end-stage population represented in hospice and palliative care enrollment.^[4]

Multiple sclerosis is an autoimmune inflammatory disease of the central nervous system in which autoreactive T-lymphocytes and B-lymphocytes breach the blood-brain barrier and attack oligodendrocytes — the myelin-producing cells that insulate nerve fibers. The result is demyelinating lesions scattered across the brain and spinal cord that disrupt every neurological function the affected fibers serve. No two patients present identically: one loses vision first, another develops cerebellar ataxia, another presents with bladder urgency and lower extremity weakness. But all progressive MS patients, regardless of initial presentation, converge toward the same clinical destination: complete neurological dependence.^[1] The patient who reaches hospice has typically lived with this disease for 20–30 years — watching themselves lose walking, then continence, then hand function, then swallowing, then speech — in whatever order this particular disease chose. They remember every function that is gone. They are an expert on their own disease in a way that no oncology patient and almost no other hospice patient is.^[2]

End-stage progressive MS — EDSS 8.0 to 9.5 — is defined clinically by the confluence of four dominant problem complexes. First, spasticity: increased muscle tone and spontaneous painful spasms that prevent comfortable positioning, disrupt sleep, impair hygiene, and drive pressure injury risk. Second, pressure injury vulnerability: the immobile patient cannot reposition independently, creating the conditions for catastrophic tissue breakdown at bony prominences. Third, bladder and bowel dependence: neurogenic dysfunction of both systems requiring catheter and bowel protocol as clinical infrastructure, not optional care. Fourth, neurological fatigue: a fatigue that is categorically different from cancer fatigue — not driven by anemia or systemic illness but by demyelination-related conduction inefficiency; it cannot be overcome by effort and does not respond to stimulants as cancer fatigue sometimes does.^[5] What makes progressive MS unique in hospice is the timeline: 20–30 years of watching this happen. The patient has not just accepted their diagnosis — they have adapted to serial losses their entire adult life. The hospice clinician who acknowledges this history explicitly provides something most clinical encounters over those decades never offered.^[6]

Recognizing when progressive MS has reached its terminal phase requires attention to trajectory rather than any single clinical marker. The patient with EDSS 9.0 who is developing recurrent aspiration pneumonia, whose weight has declined 15% over six months, and whose family has been providing 24-hour care for two years is at end of life. The disease has reached its final stage — not because it has acutely progressed, but because the cumulative neurological damage has exhausted physiological reserve. Death in MS typically results from pneumonia (aspiration or infectious), urosepsis from recurrent catheter-associated UTIs, pulmonary embolism from immobility-related DVT, or sepsis from infected pressure injuries — rarely from the demyelinating process itself.^[7]

🧭 Clinical framing: The four dominant problem complexes

Every hospice visit in end-stage MS should assess four things: spasticity control (almost always undertreated at enrollment), pressure injury status (prevent with the same urgency as preventing sepsis), bladder and bowel infrastructure (catheter patency and bowel protocol are non-negotiable safety obligations), and fatigue burden (energy conservation is a clinical strategy, not a lifestyle choice). The patient has spent 20–30 years becoming the expert on their own disease. Your first visit starts with listening, not teaching. Ask what has worked. Ask what they've never gotten enough help with. The answer will be spasticity — it almost always is.

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"You walk into an end-stage MS home and you see the whole story in under sixty seconds. The power wheelchair that no longer fits the function because they haven't sat in it for three months. The indwelling catheter with the leg bag. The air mattress — and if it's not there, that's your first clinical problem. The legs firing into extension every few minutes from spasticity that someone decided was 'managed' on baclofen 20 milligrams three times a day. You look at the patient and they are watching you assess all of this. They know more about MS than you ever will. Twenty-five years of living in a body that is slowly being dismantled will do that. Start by sitting down and saying: 'You are the expert here. Tell me what has never been well controlled, and let's start there.' The answer is going to be the spasticity. It is always the spasticity. And then you're going to fix it."

— Waldo, NP · Terminal2

S02Clinician

How It's Diagnosed

Diagnostic workup, staging, and what to look for in hospice records. Most patients arrive with an established diagnosis — this section helps you read it.

Diagnostic Workup

McDonald 2017

MRI brain and spinal cord with gadolinium contrast — Gold standard. Demonstrates demyelinating lesions in MS-typical locations. McDonald criteria 2017 require dissemination in space (lesions in ≥2 of 4 characteristic locations: periventricular, juxtacortical/cortical, infratentorial, spinal cord) and dissemination in time (simultaneous enhancing and non-enhancing lesions, or new lesion on follow-up MRI). Dawson's fingers: periventricular lesions oriented perpendicular to the corpus callosum — pathognomonic for MS on sagittal FLAIR imaging.^[8]
Cerebrospinal fluid analysis — Oligoclonal IgG bands present in >90% of MS patients; elevated IgG index. Myelin basic protein may be elevated in active demyelination. JC virus antibody index is used for PML risk stratification in patients on natalizumab — know this result if natalizumab is in the medication history. CSF in hospice context has already been done; review the results and their clinical implications.^[9]
Visual evoked potentials (VEP) — Prolonged P100 latency indicates optic nerve demyelination; confirms clinically silent lesions in patients with optic neuritis history. Useful for establishing dissemination in space in ambiguous cases.^[10]
EDSS — Expanded Disability Status Scale — The universal MS disability measure (0 = no disability; 10 = death from MS). Hospice patients typically EDSS 7.5–9.5:
- EDSS 7.0: Unable to walk >5 meters even with aid; essentially restricted to wheelchair; self-transfers
- EDSS 7.5: Unable to take more than a few steps; restricted to wheelchair; may need help with transfer; wheels self but cannot be in standard chair full day
- EDSS 8.0: Essentially restricted to bed or chair or perambulated in wheelchair but may be out of bed most of day; retains many self-care functions; generally has effective use of arms
- EDSS 8.5: Essentially restricted to bed much of day; has some effective use of arms; retains some self-care functions
- EDSS 9.0: Helpless bed patient; can communicate and eat
- EDSS 9.5: Totally helpless bed patient; unable to communicate effectively or eat/swallow
MS subtypes — RRMS (relapsing-remitting, 85% of initial diagnoses): episodic worsening with partial recovery; most DMTs designed for this subtype. SPMS (secondary progressive): insidious progression from RRMS in ~65% over 25 years; with or without superimposed relapses. PPMS (primary progressive, 15%): progressive from onset without relapsing phase; older onset (~40 years); responds poorly to most DMTs; ocrelizumab is first approved therapy.^[11]

What to Look for in Hospice Records

MS subtype (PPMS vs. SPMS) — Determines which DMTs were used and whether they are still being administered. PPMS patients are more likely to have been on ocrelizumab; SPMS patients may have transitioned through multiple agents. The subtype also informs the typical disease trajectory and time to end-stage.^[12]
Current EDSS score — Establishes functional baseline. If not documented, estimate from functional status: can patient transfer? Use arms? Communicate? Swallow? Each answer maps to an EDSS range. This score drives every medication and care decision.
DMT history and current status — What was the patient on? Has it been discontinued? If still active, who is monitoring it and what is the monitoring burden? DMT discontinuation should be documented as a formal care plan decision at hospice enrollment.
Intrathecal baclofen (ITB) pump — If present, this is the single most critical device in the record. Know the pump model, current dose (mcg/day), last refill date, and next refill due. Abrupt interruption of ITB causes severe baclofen withdrawal with hyperthermia and seizures — a potentially fatal emergency. Establish pump management continuity on day one.^[13]
Catheter type and change schedule — Indwelling urethral vs. suprapubic catheter; French size; last change date; history of UTIs, encrustation, or blockage. If catheter is overdue for change, arrange immediately.
Pressure injury history — Prior injuries, locations, stage, treatment, and current healing status. Any previous stage 3–4 injuries indicate skin integrity is already compromised and aggressive prevention protocol is mandatory.
Swallowing assessment — Prior SLP evaluation? Modified barium swallow study? Current texture level? Aspiration events? Cervical cord involvement causing dysphagia is common in advanced MS and a major aspiration pneumonia risk.
Cognitive assessment — Symbol Digit Modalities Test (SDMT) or Brief International Cognitive Assessment for MS (BICAMS) results if available. Cognitive impairment affects 40–65% of MS patients; executive dysfunction and processing speed deficits are most common. Determine who the medical decision-maker is and whether advance directives are in place.^[14]

💡 For families: What does the MS diagnosis mean?

Multiple sclerosis is a disease of the brain and spinal cord in which the body's own immune system mistakenly attacks the protective coating around nerve fibers. Over time, these attacks create areas of scarring — called lesions — that interfere with the brain's ability to send signals to the rest of the body. The diagnostic tests your loved one received — including brain scans, spinal fluid tests, and nerve studies — were done to identify these lesions and confirm the diagnosis. By the time someone with MS reaches this stage of care, those tests are part of history. What matters now is understanding what the disease has done, using that knowledge to keep your loved one as comfortable as possible, and making sure the care team has all the information they need. If you have questions about any test result in the medical records, ask the hospice nurse to explain it.

S03Everyone

Causes & Risk Factors

Modifiable and hereditary risk factors. Relevant for family conversations, genetic counseling referrals, and answering "why did this happen?"

Environmental & Modifiable Risk Factors

Epstein-Barr virus (EBV) — The most significant environmental risk factor for MS. A landmark 2022 retrospective cohort study (Bjornevik et al., Science) of 10 million US military personnel demonstrated near-universal EBV seropositivity preceding MS onset; risk of MS was 32-fold higher after EBV infection. The EBV hypothesis is now the most widely accepted causal pathway for MS; EBV vaccination may reduce MS incidence — a transformative public health implication.^[15]
Vitamin D deficiency — Low 25(OH)D levels are one of the most consistently replicated MS risk factors. Geographic distribution of MS follows sun exposure latitude (higher prevalence in Scandinavia, Canada, Australia, northern US). Vitamin D deficiency in early life and during pregnancy associated with increased MS risk. Low vitamin D also associated with more active disease and faster disability accumulation in established MS.^[16]
Tobacco smoking — Doubles the risk of developing MS and significantly accelerates disability progression once MS is established. Current smokers with MS progress to secondary progression faster than non-smokers. Smoking cessation reduces progression risk. In family counseling, acknowledge this without inducing guilt — the disease developed over decades of complex gene-environment interaction.^[17]
Obesity in adolescence — BMI >27 at age 20 associated with increased MS risk, likely through adipokine-mediated immune dysregulation and metabolic inflammation. More relevant to family history counseling than to direct patient care at this stage.
Low sun exposure and UV-B radiation — Independent of vitamin D, UV-B exposure appears to have direct immunomodulatory effects. The latitude gradient for MS prevalence is one of the most robust epidemiological findings in the disease.^[16]
Organic solvent exposure — Trichloroethylene and other chlorinated solvents have emerging evidence for modestly increased MS risk, particularly in occupationally exposed individuals.

Genetic & Non-Modifiable Risk Factors

HLA-DRB1*15:01 allele — The strongest single genetic risk factor for MS. Carriers have approximately 3-fold increased risk. This MHC class II allele influences antigen presentation and autoreactive T-cell activation. Multiple additional susceptibility loci have been identified (IL7RA, IL2RA, TNFRSF1A) through GWAS studies, confirming MS as a polygenic disease.^[18]
Family history — Sibling risk of MS is 3–5% (vs. ~0.1% in general population). Parent-to-child risk approximately 2–3%. Identical twin concordance 25–30%, confirming both strong genetic component and essential environmental contribution. Fraternal twin concordance ~5%, similar to non-twin siblings.^[18]
Sex — Female:male ratio 3:1 for RRMS; ratio narrows to approximately 1.5:1 for PPMS. Hormonal factors including pregnancy (which reduces relapse rate via immune modulation) and postpartum period (which increases relapse risk) demonstrate the role of sex hormones in MS disease activity.
Age — RRMS: peak onset 20–40 years. PPMS: onset typically 40–60 years, with later diagnosis and more rapid disability accumulation relative to disease duration.
Racial and ethnic disparities — Black Americans with MS have more aggressive disease, more rapid disability accumulation, greater spinal cord involvement, and later diagnosis compared to white Americans. Black patients are also less likely to be offered or receive high-efficacy DMTs. These disparities are not explained by disease biology alone — structural racism and healthcare access barriers contribute substantially. In hospice, late diagnosis may mean a shorter history of DMT use but equally advanced disability.^[19]
Geography — MS prevalence increases with distance from the equator in both hemispheres. The US prevalence is higher in northern states. Immigration studies show that risk is partly determined by childhood environment, not just genetics.

❤️ For families: "Why did this happen?"

This is one of the most common questions families carry — and one of the most painful. Multiple sclerosis is an autoimmune disease. It was not caused by anything your loved one did, ate, chose, or failed to do. There is no lifestyle failure here. MS results from a complex interaction of genetic predisposition and environmental exposures — including a very common virus that most people are exposed to in childhood, and factors like sun exposure and vitamin D levels that no one chooses deliberately. The best researchers in the world spent decades unraveling why some people develop MS and others do not. The answer is not your loved one's fault. If you are carrying guilt about this — whether as a family member who shares their genetics or as someone who wonders what you could have done differently — please bring that to the care team. This is grief that deserves to be spoken out loud.

⚕ Clinician note: Family history conversation in MS

MS genetic risk is fundamentally different from germline cancer syndromes. There is no single gene that, if inherited, confirms MS in the next generation. The sibling risk of 3–5% and parent-to-child risk of 2–3% are real but modest — the absolute majority of first-degree relatives will not develop MS. Genetic testing is not clinically useful for MS risk prediction at this time. The family history conversation should acknowledge the risk honestly, note that it is low in absolute terms, recommend vitamin D supplementation and smoking cessation in at-risk relatives as potentially modifiable factors, and avoid creating unnecessary anxiety. Acknowledge racial disparities explicitly with Black patients and families — the later diagnosis and less aggressive DMT treatment they may have received are systemic failures, not personal failures, and deserve naming in a hospice context that invites honest conversation about their disease course.

S04ClinicianEveryone

Treatments & Procedures

What disease-directed treatments this patient may have received or may still be receiving. Understanding prior therapy helps anticipate complications and interpret the patient's trajectory.

The disease-modifying therapy landscape in MS spans four decades of development — from injectable interferons in the 1990s to high-efficacy anti-CD20 monoclonal antibodies now approved for both relapsing and progressive disease. By the time a patient with progressive MS reaches hospice, they have typically moved through multiple DMT lines: years on injectable therapy, a transition to oral agents as disease progressed, and possibly high-efficacy therapy as neurologists attempted to slow the accumulating disability. Understanding this history matters in hospice because DMTs carry monitoring burdens, laboratory requirements, and infusion schedules that are often clinically inconsistent with comfort goals — and the hospice team is often the first to name this explicitly. The core clinical work in end-stage MS hospice is not disease modification; it is the aggressive, expert management of spasticity, pressure injury prevention, bladder and bowel infrastructure, fatigue, pain, and dysphagia.^[20]

Disease-Modifying Therapies (DMTs)

Injectable first-line (moderate efficacy) — Interferon beta-1a (Avonex, Rebif), interferon beta-1b (Betaseron, Extavia), glatiramer acetate (Copaxone, Glatopa). First agents approved for RRMS; some patients have been on these for 20+ years. Subcutaneous or intramuscular injection. Largely superseded for active disease by higher-efficacy oral and infusion agents but relevant because patients may still be on them at enrollment.^[21]
Oral moderate-to-high efficacy — Dimethyl fumarate (Tecfidera): lymphopenia risk; CBC monitoring. Teriflunomide (Aubagio): teratogenic; LFT monitoring; very long half-life. Siponimod (Mayzent): S1P modulator approved specifically for SPMS with active disease — first oral therapy with regulatory approval for secondary progressive MS; cardiac monitoring at initiation. Ozanimod, ponesimod: S1P modulators approved for RRMS.^[22]
High-efficacy infusion therapies — Natalizumab (Tysabri): anti-VLA-4; monthly infusion; PML risk requiring JC virus antibody index monitoring (contraindicated at high JC index); highly effective RRMS. Ocrelizumab (Ocrevus): anti-CD20 B-cell depletion; approved for both RRMS and PPMS (only high-efficacy agent approved for PPMS; ORATORIO trial); semi-annual infusion. Ofatumumab (Kesimpta): anti-CD20; self-injected monthly. Alemtuzumab (Lemtrada): powerful immune reconstitution; serious autoimmune adverse effects; surveillance burden for years after. HSCT: hematopoietic stem cell transplantation — aggressive immune ablation and reconstitution; used at specialized centers.^[23]
The DMT discontinuation decision in hospice — Evidence does not support continuing most DMTs at EDSS >7.0 with no active inflammatory disease. The benefit of DMTs is reduction of relapses — which are less frequent or absent in advanced progressive MS; DMTs do not reverse established disability. Monitoring burden (monthly MRI for natalizumab, CBC for cladribine, LFT monitoring for teriflunomide/dimethyl fumarate) is inconsistent with comfort goals. Exception: ocrelizumab in PPMS has disease-modifying benefit that may extend further in the disease course — discuss explicitly with the neurologist before discontinuing. The decision to stop DMTs should be documented as a formal comfort-focused care plan item, not abandoned silently.^[24]

Symptom Management — The Core Clinical Work

Spasticity management — The dominant and most undertreated symptom in end-stage MS. Oral baclofen (GABA-B agonist, 10–80 mg/day in divided doses) is first-line; tizanidine (alpha-2 agonist, 4–8 mg TID) as adjunct; diazepam (2–10 mg TID) particularly for nocturnal spasms and anxiety; cannabinoids (oral or oromucosal); intrathecal baclofen (ITB) pump for refractory cases. Never stop baclofen abruptly — withdrawal causes seizures and hyperthermia. ITB pump management requires specialist coordination and must be addressed at enrollment.^[25]
Pressure injury prevention and management — The clinical obligation: repositioning every 2 hours in bed, every 1 hour in wheelchair; alternating pressure or air-fluidized mattress; moisture management; barrier creams; daily skin inspection; protein and micronutrient support. Established injuries require wound care as comfort intervention — reducing pain, odor, and infection risk. This is comfort care, not curative care.
Bladder management — Indwelling urethral or suprapubic catheter is standard at EDSS 8.0+. Review catheter type, size, and change schedule. UTI prevention with proper catheter care, acidifying supplements (ascorbic acid), and methenamine if tolerated. Prophylactic low-dose antibiotics (trimethoprim 100 mg nightly or nitrofurantoin 50 mg nightly) for patients with recurrent symptomatic UTIs causing fever and distress.^[26]
Bowel program — Neurogenic bowel is universal at EDSS 8.0+. Scheduled suppository (bisacodyl or glycerin) or digital rectal stimulation every 48 hours. Impaction causes autonomic dysreflexia, pain, agitation, and can trigger a spasm crisis. The bowel program is non-optional — it is infrastructure, not symptom management.
Pain management — Neuropathic pain (gabapentin 300–900 mg TID, pregabalin, duloxetine, amitriptyline) for burning, tingling, electric-shock dysesthesias. Spasticity-related musculoskeletal pain treated with antispasticity medications. Central pain syndromes may require low-dose opioids in carefully titrated doses.
Fatigue management — Energy conservation, scheduled rest, activity pacing. MS fatigue is neurological — not responsive to effort or stimulants at advanced EDSS. Eliminate unnecessary fatigue-inducing activities. Heat avoidance is critical (Uhthoff phenomenon — neurological symptoms worsen dramatically with temperature elevation).
Dysphagia management — SLP assessment; modified texture diet for cervical cord involvement; aspiration precautions; positioning during meals. Aspiration pneumonia is a leading cause of MS-related death.

S05Clinician

When Therapy Makes Sense

Evidence-based criteria for continuing disease-directed therapy. This is not about giving up or holding on — it's about reading the data correctly.

In end-stage progressive MS, symptom-directed therapy is not a consolation prize — it is the primary clinical work. The distinction between "disease-directed" and "comfort-directed" therapy collapses in MS hospice: aggressive spasticity management, expert catheter and bowel care, pressure injury prevention, and dysphagia management are evidence-based interventions that directly reduce suffering, prevent life-threatening complications, and preserve function and dignity. None of them require an oncology consult or a disease-modifying mechanism. They require clinical expertise, consistent execution, and the willingness to optimize what has never been adequately managed. The clinical question is not whether therapy makes sense — it is which therapy, in what dose, with what monitoring, for which specific symptom complex that is today causing the most suffering.^[25]

01

Baclofen dose optimization for spasticity — The single most important therapeutic intervention at every MS hospice enrollment. Spasticity is almost universally undertreated at the time of hospice intake: patients arrive on baclofen 20–30 mg/day with spasm ratings of 7–8/10. This represents inadequate titration, not maximal management. Titrate oral baclofen from the current dose toward 60–100 mg/day in divided doses (typically 4 doses/day), adding increments of 5–10 mg every 3–5 days while monitoring sedation and muscle weakness. Add tizanidine 4–8 mg TID as adjunct (additive benefit, different mechanism). Add diazepam 2–5 mg at bedtime for nocturnal spasms (also addresses anxiety from spasm-related distress). Consider cannabis/cannabinoids where available — oromucosal administration is preferred. Evaluate for intrathecal baclofen (ITB) pump if oral therapy is inadequate despite optimization: ITB pump delivers baclofen directly to CSF at doses 100–1000× lower than oral, eliminating sedation while providing dramatically superior spasticity control.^[25]
02

Pressure injury wound care for established injuries — Even in purely comfort-focused goals of care, wound care is a comfort intervention, not a curative one. An open stage 3 or 4 pressure injury in an MS patient with spasticity causes severe pain, infection risk, and odor that affects the patient's dignity and the family's caregiving experience. Evidence-based wound care — appropriate debridement method, moisture-balance dressings (foam, alginate, hydrocolloid based on exudate level), infection management, offloading — reduces all of these burdens. Document wound assessment at every visit. Involve wound care specialist if available. Nutritional support (protein 1.2–1.5 g/kg/day, vitamin C 500 mg BID, zinc 25 mg/day) accelerates healing even in patients on comfort-focused goals.^[27]
03

Bladder management optimization — Review the catheter system comprehensively at enrollment and at each visit: Is the catheter the correct French size for this patient (typically 14–16 Fr; larger sizes in patients with recurrent encrustation)? When was it last changed (standard monthly for latex; silicone can go longer)? Is the drainage bag positioned correctly to prevent reflux? Is the connecting tubing kinked or compressed? If recurrent UTIs are causing fever and distress, initiate prophylactic antibiotics — trimethoprim 100 mg nightly or nitrofurantoin macrocrystals 50–100 mg nightly is appropriate comfort-focused antibiotic prophylaxis in catheterized MS patients; document the rationale as symptom burden reduction. Ascorbic acid 500 mg BID for urinary acidification is an adjunct. Suprapubic catheter is preferable to urethral catheter for long-term catheterization in female patients and those with urethral sensitivity from spasticity-related positioning.^[26]
04

Bowel program — scheduled and non-optional — Neurogenic bowel in advanced MS requires a scheduled protocol: bisacodyl suppository (10 mg) or glycerin suppository with or without digital rectal stimulation every 48 hours, at a consistent time of day. Bowel program failure causes impaction, which causes autonomic dysreflexia (headache, hypertension, flushing, bradycardia), severe pain, agitation, and frequently triggers a spasm crisis that will not resolve until the impaction is treated. Ensure the family understands the bowel program is not optional and not gross — it is medical care that prevents a crisis. If impaction occurs: manual disimpaction with lidocaine gel for comfort, followed by a tap water enema, followed by reassessment of the bowel protocol frequency and the adequacy of oral hydration. Docusate sodium is generally insufficient alone; osmotic laxatives (polyethylene glycol, lactulose) may supplement the scheduled suppository program.^[28]
05

Dysphagia management — SLP assessment for cervical cord involvement — Dysphagia in MS results from cervical cord demyelination affecting the coordinated pharyngeal swallowing mechanism, brainstem involvement affecting the swallowing center, or cerebellar ataxia affecting the oral and pharyngeal phases. If not previously assessed, SLP evaluation is appropriate at hospice enrollment for any patient with coughing during meals, unexplained recurrent respiratory illness, or visible difficulty swallowing. Modified texture diets (IDDSI framework: minced/moist, pureed) and thickened liquids (nectar or honey consistency) reduce aspiration risk while preserving oral intake. Upright positioning during and for 30 minutes after meals. Small, frequent meals rather than three large meals. Aspiration precautions documented and taught to family caregivers. As disease progresses to EDSS 9.5, oral intake may become impossible — the advance care planning conversation about artificial nutrition should occur before this point, not after.^[29]
06

Cannabinoids (nabiximols/Sativex) for spasticity, pain, and bladder urgency — Nabiximols (oromucosal THC:CBD 2.7 mg:2.5 mg per spray) is the only cannabis-based medicine with specific regulatory approval for MS spasticity, approved in the UK, Canada, and multiple European countries. The evidence base for cannabis in MS spasticity is the strongest of any hospice indication for cannabis — multiple RCTs (including the MOVE2 trial) demonstrating reduction in spasticity-related pain, spasm frequency, and bladder urgency. Titrate from 1 spray at bedtime to a maximum of 12 sprays per day distributed across the day as needed. In US states without nabiximols access, oromucosal cannabis tinctures (sublingual THC:CBD balanced products) provide clinically similar benefit. Cannabis also reduces neuropathic pain and sleep disturbance — the combination of spasticity reduction, pain relief, and sleep improvement makes cannabinoids an exceptionally high-value intervention in end-stage MS.^[30]
07

Fampridine (dalfampridine) continuation — if patient retains valued walking function — Fampridine (Ampyra, 10 mg extended-release twice daily) is a potassium channel blocker that improves nerve conduction in demyelinated axons, modestly improving walking speed and distance in approximately 35–40% of responders (ENHANCE trial). For a patient at EDSS 5.5–6.5 who has been walking with assistance using fampridine and who explicitly values preserving any remaining ambulatory function, continuation is appropriate even in a hospice context where the primary goal is comfort — because maintaining the ability to walk a few steps to the commode represents a major quality-of-life difference. Reassess the benefit explicitly: is the patient walking more than they would without it? If response is uncertain, a 2-week trial off fampridine with careful functional observation will clarify. Discontinue when it no longer confers a walking benefit the patient values.^[31]

S06Clinician

When It Doesn't

Knowing when treatment stops helping is not clinical failure. It is the most important clinical skill in this disease.

The failure of clinical judgment in end-stage MS rarely looks like aggression — it looks like inertia. The neurologist still ordering monthly MRIs in a bedridden EDSS 9.0 patient. The primary care physician refilling baclofen 20 mg TID without ever asking about spasm control. The care team continuing natalizumab infusions because no one initiated the discontinuation conversation. In progressive MS, the burden of proof for continuing any intervention that is not directly reducing symptoms should be explicit and documented. The interventions below are not simply unnecessary — they impose measurable burden on patients who are already at the limit of their functional reserve, and some of them may actively extend the dying process rather than improve its quality.^[24]

01

DMT discontinuation at EDSS >7.0 with no active inflammatory disease — The evidence for disease-modifying therapy benefit in advanced progressive MS with no active relapses and no MRI disease activity is absent. DMTs reduce relapse rate; at EDSS >7.0 in a patient with progressive MS who has not relapsed in years, there are no relapses to reduce. The disability that is present will not improve with continued DMT. What continues is the monitoring burden: monthly labs for some agents, monthly infusions for natalizumab, regular MRI surveillance, clinic appointments requiring transport that patients cannot manage, and infusion reactions. All of this burden is imposed on a patient whose goals are comfort and home time. The exception to discuss explicitly with the neurologist is ocrelizumab in PPMS, where there is evidence of sustained benefit in reducing confirmed disability progression even in advanced disease — but even here, the conversation must weigh infusion burden against benefit at this stage. Document the DMT discontinuation decision in the care plan.^[24]
02

Artificial nutrition in advanced MS with dysphagia and cognitive impairment — The evidence that tube feeding prevents aspiration pneumonia in patients with progressive neurological disease is unambiguous: it does not. Aspiration in advanced MS occurs because of neurological dysfunction of the swallowing mechanism — a gastrostomy tube bypasses oral intake but does not eliminate aspiration of oral secretions, which is the primary mechanism of aspiration pneumonia in neurological disease. The same evidence base that guides this decision in Parkinson's disease dementia and advanced ALS applies here. Tube feeding in this context extends the dying process without improving quality of life and may add discomfort from the tube, increased secretions, and bloating. This conversation belongs early in the hospice relationship — ideally documented in advance directives before swallowing failure creates a crisis in which the family feels they must choose between "feeding" their loved one and "letting them die." Frame it as: the disease has affected the nerves that control swallowing; feeding through a tube does not fix those nerves and does not prevent the pneumonias this disease causes.^[32]
03

IV antibiotics for recurrent UTIs in the actively dying patient — Recurrent UTIs are essentially universal in catheterized MS patients. In a patient who is not actively dying, comfort-focused prophylactic antibiotic use is appropriate (see S05). But when a patient is clearly in the final days of life — unresponsive or minimally responsive, not eating or drinking, extremities mottling — fever from a UTI does not change the prognosis and IV antibiotics requiring hospitalization or IV access are not consistent with comfort-focused home death. Fever management with acetaminophen (rectal or via PEG if oral not possible) is sufficient and appropriate. The family should be prepared for this conversation before the final decline begins: "If a fever develops in the last days, we will focus on keeping him/her comfortable; antibiotics at that point would require going to the hospital and would not change the outcome we are expecting." Document this plan explicitly in the comfort care orders.^[33]
04

High-dose corticosteroids for pseudo-relapses in end-stage MS — In end-stage progressive MS, acute functional worsening is almost never a true demyelinating relapse. It is a pseudo-relapse: neurological decompensation triggered by a physiological stressor — most commonly UTI, pressure injury infection, fever, pain, constipation, or medication change. True relapses are characterized by new neurological deficits lasting more than 24 hours without a precipitant; pseudo-relapses mirror existing deficits and resolve when the trigger is treated. High-dose methylprednisolone (1 g IV × 3–5 days) for a pseudo-relapse carries the side effect burden of steroids (hypertension, hyperglycemia, insomnia, agitation, fluid retention, GI bleeding) without benefit — because the underlying neurological infrastructure that was functioning before the stressor has not been acutely damaged. Treat the cause: find and treat the UTI, the impaction, the pressure injury, the uncontrolled pain. The functional status will return toward baseline as the stressor resolves.^[34]
05

Stimulant medications for fatigue at EDSS >8.0 — MS fatigue at EDSS >7.5–8.0 is not driven by reversible metabolic or motivational mechanisms. It reflects the cumulative neurological cost of signal conduction through severely demyelinated networks — a biophysical ceiling that no stimulant medication overcomes. Amantadine (the traditional first-line for MS fatigue), modafinil, and methylphenidate have evidence in ambulatory MS patients with moderate fatigue; at EDSS >8.0, there is no functional activity remaining for which fatigue reduction would be a meaningful benefit, and stimulants add agitation, insomnia, cardiovascular stress, and appetite suppression in a patient who may already have inadequate nutritional intake. The clinical goal shifts explicitly from fatigue management to rest facilitation: scheduled rest periods, reducing unnecessary activity, managing the environmental stressors (spasm-related sleep disruption, nocturia) that compound neurological fatigue. If a family interprets rest as "giving up," this framing needs to be explicitly corrected: energy conservation is a clinical prescription, not surrender.^[5]

📋 Clinician note: The false binary and the neurologist still ordering MRIs

The hospice team will frequently encounter neurologists who remain in disease-modification mode for patients who are clearly at end of life. This is not malice — it is the natural momentum of a specialty organized around slowing the disease rather than managing the dying. The neurologist may have treated this patient for 20 years. The care team has been through every DMT transition, every relapse, every EDSS step. Disengaging from that role is not simple, even when the evidence and the patient's functional status make it clinically clear. The hospice NP's role is not to be adversarial but to be explicit: "We need to discuss which monitoring activities and treatments serve your patient's current goals of comfort and home time, and which create burden without benefit at this stage." Bring the EDSS score, the functional status, and the goals-of-care documentation. The conversation is easier when the neurologist sees that the hospice team has the clinical facts organized — and that this is a transition in care, not an abandonment of the patient.

S07Everyone

Out-of-the-Box Approaches

Evidence-graded integrative, interventional, and complementary approaches. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.

Intrathecal Baclofen (ITB) Pump for Refractory Spasticity

Grade A

Dose: Intrathecal baclofen 50–800 mcg/day via programmable implanted pump; typically initiated at 25–50 mcg/day and titrated to effect over weeks to months

ITB pump therapy delivers baclofen directly to the cerebrospinal fluid via an implanted intrathecal catheter and programmable pump reservoir, achieving equivalent or superior spasticity control at doses 100–1000× lower than required orally — thereby eliminating the sedation and cognitive side effects that limit oral baclofen titration. Multiple RCTs and registry data demonstrate dramatically superior spasticity control compared to oral baclofen, with significant reductions in Ashworth Scale scores, spasm frequency, pain, and sleep disturbance.^[35] The pump is programmable for diurnal variation — lower rates during waking hours to preserve tone for transfers, higher rates at night to prevent nocturnal spasms. Reservoir requires refill every 2–6 months depending on dose and reservoir size. Even in patients at EDSS 8.0–9.0 who have never had ITB, pump placement can transform quality of life by eliminating the painful spontaneous spasms that dominate the symptom experience. Critical warning: NEVER stop ITB pump abruptly. Abrupt withdrawal of intrathecal baclofen causes severe baclofen withdrawal syndrome: hyperthermia, seizures, muscle rigidity, rhabdomyolysis, and autonomic instability that can be fatal. If pump malfunction is suspected, treat as medical emergency with IV or oral baclofen bridge and benzodiazepines while arranging urgent pump evaluation. At end of life, ITB dose weaning must be planned in advance with the implanting neurosurgeon or physiatrist.^[13]

Nabiximols (Sativex) — Oromucosal Cannabis Spray

Grade A

Dose: THC 2.7 mg : CBD 2.5 mg per oromucosal spray; initiate 1 spray at bedtime; titrate by 1 spray/day over 1–2 weeks to maximum 12 sprays/day; distribute doses throughout the day

Nabiximols (Sativex) is the only cannabis-based medicine with specific regulatory approval for MS spasticity — approved in the UK, Canada, and more than 25 countries. The MOVE2 trial and multiple predecessor RCTs demonstrate statistically significant and clinically meaningful reductions in patient-rated spasticity, neuropathic pain, and bladder urgency in MS patients inadequately controlled on existing antispasticity therapy.^[30] The evidence base for cannabis in MS spasticity is the strongest of any hospice indication for cannabis medicine. Oromucosal delivery provides predictable absorption with faster onset than oral ingestion and without the respiratory risks of smoked or vaporized cannabis. The balanced THC:CBD ratio reduces psychotomimetic effects compared to high-THC products. In US states without nabiximols availability, balanced THC:CBD sublingual tinctures (1:1 ratio) provide clinically similar benefit. Primary indications in MS hospice: spasticity pain, nocturnal spasms disrupting sleep, neuropathic pain, bladder urgency and frequency, and generalized anxiety from chronic pain and immobility. No clinically significant drug interactions with baclofen, tizanidine, or opioids at standard doses.^[36]

Air-Fluidized or Alternating Pressure Mattress

Grade A

Protocol: Prescribe at enrollment for EDSS 8.5–9.5; alternating pressure mattress (cycle time 10–12 min) as minimum standard; air-fluidized bed for established stage 3–4 injuries or patients with multiple risk factors

Pressure redistribution mattresses are the highest-evidence single intervention for pressure injury prevention and treatment in immobile patients. NICE guidelines and EPUAP/NPIAP international guidelines designate high-specification active support surfaces as standard of care for patients who cannot independently reposition — which describes every MS patient at EDSS 8.5–9.5.^[27] For the MS patient with spasticity who fires into extension during repositioning, an alternating pressure mattress reduces the mechanical pressure exposure between manual repositioning events, extending safe repositioning intervals when family caregivers cannot maintain 2-hour schedules through the night. Air-fluidized beds (Clinitron-type) disperse pressure across the entire body surface and are appropriate for patients with established stage 3–4 injuries or sacral/ischial wounds complicated by spasticity-driven shear. These are not luxury items — they are clinical prescriptions. The hospice team that does not assess mattress type at enrollment and prescribe an appropriate surface for a fully immobile MS patient is providing incomplete care. Document mattress type in the assessment and escalate with the hospice medical director if insurance authorization is delayed.

Botulinum Toxin for Focal Spasticity

Grade A

Dose: 200–400 units botulinum toxin type A (onabotulinumtoxin A or abobotulinumtoxin A) per treatment session into affected muscle groups; repeat every 3 months; ultrasound or EMG guidance preferred for precision

Botulinum toxin injection into focally hypertonic muscle groups provides targeted spasticity relief that oral antispasticity medications cannot achieve — without systemic sedation or cognitive effects. Multiple RCTs in MS spasticity demonstrate significant reductions in Ashworth Scale scores and improvement in passive range of motion at injected sites.^[37] In end-stage MS, the primary clinical applications are: hip adductor spasticity causing scissoring that impedes catheter care and hygiene; plantarflexor spasticity causing foot deformity and skin breakdown at contact points; elbow/wrist flexor spasticity causing maceration in flexor creases; and cervical dystonia from spastic neck muscles preventing comfortable head positioning. These are not cosmetic concerns — untreated focal spasticity in these patterns directly causes skin breakdown, hygiene failure, and positioning pain that drives the entire symptom burden. Botulinum toxin can be administered in a home or outpatient setting, typically by a physiatrist or neurologist. In hospice, the benefit must be weighed against the transport burden — for patients who cannot be transported, consider whether the hospice team can facilitate home-visit injection through specialist coordination.

Therapeutic Cooling (Uhthoff Management)

Grade B

Protocol: Cooling vest worn 30–60 min during periods of activity or elevated ambient temperature; room temperature maintained at 68–72°F (20–22°C); cooling collar or wrist wraps as adjuncts; cool beverages pre-activity

The Uhthoff phenomenon — transient worsening of MS neurological symptoms with increases in core or ambient temperature — occurs because elevated temperature impairs conduction in already-demyelinated axons that can only maintain function within a narrow temperature window. Even a 0.5°C increase in core temperature can cause dramatic, temporary functional deterioration in MS patients: increased weakness, worsening spasticity, visual blurring, and profound fatigue.^[38] Multiple observational and controlled studies demonstrate that active cooling — using commercially available cooling vests, room temperature control, or cool water immersion — reduces fatigue, improves function, and reduces spasm frequency in heat-sensitive MS patients. In end-stage MS, therapeutic cooling primarily addresses: care activities (bathing, repositioning, dressing changes create exertion-related heat), environmental temperature (summer heat or overheated rooms), and fever from infections. Maintaining room temperature at 68–72°F is the most cost-effective intervention. For caregivers: explain the Uhthoff phenomenon explicitly — "Your family member's symptoms can worsen temporarily when they get warm; this does not mean the disease has progressed; it means we need to keep them cooler."

Music Therapy

Grade B

Protocol: 30–60 minute individualized sessions, 1–3 times per week; live or recorded; patient-selected music preferred; neurologic music therapy techniques (rhythmic auditory stimulation) for spasticity; receptive listening for anxiety/pain

Music therapy in MS has evidence from multiple RCTs and controlled trials demonstrating reductions in spasticity, pain, anxiety, and depressive symptoms.^[39] The neurological mechanism is not fully elucidated but likely involves auditory-motor entrainment (rhythmic auditory stimulation synchronizes motor neuron firing, modulating spastic tone), endogenous opioid and dopamine release via music-evoked pleasure responses, and parasympathetic activation reducing autonomic-driven spasm triggers. In end-stage MS with communication impairment, music therapy is one of the few interventions that bypasses verbal language and accesses the patient's inner experience directly — particularly valuable in patients whose cognitive or communication changes have limited their ability to express emotional distress verbally. Patient-directed music selection is essential: the emotional valence of specific music is personal and powerful; the wrong music can increase distress. Certified neurologic music therapists (NMT) are the standard for this intervention; hospice music therapists without specific NMT training can provide receptive listening and music-based relaxation with good effect. Particularly valuable for existential distress, isolation, identity grief, and the fatigue of a 25-year disease course.

Low-Dose Naltrexone (LDN)

Grade C

Dose: 1.5–4.5 mg orally at bedtime (vs. the standard opioid-antagonist dose of 50 mg/day); compounding pharmacy required; start at 1.5 mg and titrate over weeks

Low-dose naltrexone (LDN) operates through a mechanism distinct from standard naltrexone: brief intermittent opioid receptor blockade at low doses induces compensatory upregulation of endogenous opioid production (endorphins, enkephalins), with secondary anti-inflammatory and neuroimmune modulating effects via microglial TLR4 antagonism. Small RCTs and observational studies in MS specifically (Cree et al., 2010; Bowling et al.) show modest but suggestive improvement in fatigue, pain, and quality of life, particularly in RRMS and early SPMS.^[40] The evidence base is limited — no large RCTs in end-stage progressive MS. LDN has a favorable safety profile at doses below 5 mg/day and is generally well-tolerated. Critical interaction: LDN is incompatible with opioid analgesia — even at low doses, naltrexone will precipitate opioid withdrawal and block opioid efficacy. If the patient is taking or is likely to need opioid pain management, LDN is contraindicated. This interaction is the primary limiting factor for use in symptomatic end-stage MS. If opioids are not part of the pain regimen and are not anticipated, LDN is a reasonable option for patients who have found benefit from it previously.

Psilocybin-Assisted Therapy for Existential Distress

Grade D

Protocol: Psilocybin 20–25 mg in a single supervised session within a structured therapeutic framework; requires trained facilitator; currently restricted to clinical trial enrollment or specific state-legal programs (Oregon, Colorado)

Psilocybin-assisted therapy for existential distress, depression, and anxiety at end of life has generated significant evidence in cancer populations — the Johns Hopkins and NYU trials demonstrated large-effect-size, durable reductions in existential anxiety and depression following a single supervised psilocybin session, with effects persisting 6–12 months.^[41] No MS-specific trial data exist. The rationale for consideration in end-stage progressive MS is strong on theoretical grounds: patients face a unique existential burden — 20–30 years of watching their own dismantling, the loss of every identity-defining function, the cognitive dissonance of a mind that remembers everything it could once do inside a body that can no longer do any of it. This existential burden is distinct from cancer-related death anxiety; it includes accumulated grief, identity dissolution, and the exhaustion of decades of adaptation. Psilocybin's mechanism — promoting neuroplasticity and disrupting entrenched patterns of negative self-referential processing — may address this specific existential profile. Not currently appropriate outside of clinical trial enrollment or state-regulated programs. Include in advance care planning discussions with patients who express interest; assist with clinical trial identification if the patient's functional status permits participation.

S08Everyone

Natural & Herbal Options

Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to this diagnosis. Patients will use supplements — this section helps you have the right conversation.

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"Patients with MS have been researching supplements since the month they were diagnosed. They've been on this for 25 years. Don't dismiss what they've found — ask what they're taking, ask why, and then talk about interactions. Most of the time they know more about vitamin D and MS than you do. Meet them there."

— Waldo, NP · Terminal2

Herb / Supplement	Evidence Grade	Typical Dose	Potential Benefit	⚠ Interactions / Contraindications
Vitamin D Target 25(OH)D 40–60 ng/mL	Grade B	2,000–4,000 IU daily (corrective dosing); recheck level in 3 months	Deficiency is one of the most replicated MS risk and activity factors; correction associated with reduced disease activity; widely used and supported throughout MS community	Monitor calcium with high doses; safe at standard corrective doses; no meaningful interaction with most DMTs
Omega-3 Fatty Acids Fish oil / EPA+DHA	Grade C	1 g/day (EPA+DHA combined); do not exceed at hospice unless neurologist recommends	Anti-inflammatory; modest observational signal for MS activity reduction; generally safe at 1 g/day	⚠ Antiplatelet effect — caution with anticoagulation for DVT prophylaxis (common in immobile MS patients); avoid doses >1 g/day in this setting
Melatonin	Grade C	3–10 mg at bedtime; start 3 mg, titrate up	Sleep disruption is near-universal in end-stage MS from nocturnal spasms, nocturia, and pain; melatonin is safe and well-tolerated; preclinical neuroprotective signal	Potentiates CNS depressants (baclofen, diazepam, opioids) — start low; minor interaction with warfarin; generally very safe in this population
Magnesium Glycinate Preferred chelated form	Grade C	200–400 mg at bedtime	May reduce spasticity through NMDA receptor modulation and improve sleep; well-tolerated in chelated form; supports muscle relaxation	⚠ Monitor with renal impairment — accumulates in kidney disease; GI loosening (beneficial in MS constipation); enhances effect of baclofen/diazepam
Turmeric / Curcumin	Grade C	500–1,000 mg BID with black pepper (piperine) for bioavailability	Anti-inflammatory; NF-κB inhibition; preclinical MS models show neuroprotection; widely used by MS patients	⚠ Antiplatelet interaction — caution with anticoagulation; may inhibit CYP3A4 at high doses; GI upset if taken without food
Alpha-Lipoic Acid (ALA)	Grade C	600 mg daily	Antioxidant; neuroprotective preclinical data in MS models; one small RCT showed slowing of brain atrophy in SPMS; generally well-tolerated	Mild GI effects; may lower blood glucose — monitor in diabetics; no major drug interactions at standard doses
Probiotics Multi-strain formulation	Grade C	Multi-strain probiotic; dose varies by product; refrigerated preferred	Gut-brain axis dysbiosis documented in MS; observational data for symptom improvement; neuroinflammation modulation; particularly relevant for MS bowel dysfunction	Generally safe; use with caution in severely immunocompromised patients (rare concern in MS hospice); no significant drug interactions
Cannabis — Whole Plant Oral / oromucosal preferred; nabiximols (Sativex) where available	Grade B	Variable; oromucosal: 1–2 sprays at night, titrate to 12 sprays/day max; oral: low-dose THC:CBD ratio product	Strongest evidence of any supplement for MS spasticity. Multiple RCTs support nabiximols for spasticity, neuropathic pain, and bladder urgency; approved in UK, Canada, and multiple EU countries for MS spasticity specifically	Legal access varies by US state; CNS depression with baclofen/diazepam — start low, titrate; psychoactive effects at higher THC doses; cannabis-drug interactions via CYP450 system; driving contraindicated

🚫 Avoid in Progressive MS — Contraindicated or High-Risk Supplements

Echinacea: Immunostimulant — theoretically contraindicated in MS; may re-activate autoimmune pathways that DMTs are designed to suppress; explicitly advise against use in any patient still on immunomodulatory therapy
Ginseng (Panax): Immunostimulant properties with theoretical risk of MS immune reactivation; also has CNS stimulant effects that may worsen MS fatigue rebound and sleep disruption
Astragalus: Potent immune-stimulating herb — theoretical autoimmune activation risk; avoid in progressive MS
St. John's Wort (Hypericum perforatum): CYP3A4 inducer — reduces blood levels of multiple DMTs including fingolimod, siponimod, natalizumab metabolism products, and baclofen; interacts with multiple other MS medications; contraindicated
Kava (Piper methysticum): Hepatotoxicity risk is compounded by DMT-associated hepatotoxicity (teriflunomide, dimethyl fumarate); CNS depression interacts dangerously with baclofen and diazepam; avoid entirely
High-dose Biotin (MD1003, 100–300 mg/day): Initially promising for progressive MS neuroprotection; Phase III trial (SPI2 trial) failed to show meaningful benefit; most critically — high-dose biotin causes severe interference with multiple laboratory immunoassays including troponin, TSH, and vitamin D levels, potentially leading to dangerous clinical misinterpretation; do not use at doses above standard nutritional supplementation

S09Everyone

Timeline Guide

A guide, not a prediction. Every patient's trajectory is shaped by histology, molecular profile, treatment response, and comorbidities.

The MS timeline is the longest of any diagnosis in this hospice library — 20 to 30 years from first symptom to end stage. No other hospice diagnosis asks a patient to carry their disease for decades while remaining cognitively aware of every function lost. Use this guide to orient the family and clinical team to where the patient is in that arc — and to recognize that the patient at hospice has already passed through phases that most other hospice patients never see. What is "early" in MS may be a decade ago. What is "terminal" may have been building for years. Every phase deserves acknowledgment.^[5]

YRS–
MOS

Phase 1: Diagnosis & Relapsing Phase

RRMS with relapses managed by disease-modifying therapy; patient is functionally active — working, raising children, building a career; MS has entered their life but has not yet taken over it
Palliative care is essentially never offered at this stage, and advance care planning conversations are extremely rare; this is the most valuable window for those conversations — the patient can articulate their values, designate proxies, and complete advance directives while fully functional
The patient diagnosed at 30 who completes an advance directive at 32 has an enormous advantage over the patient who must make those decisions from a wheelchair at 55 — the hospice team will inherit either outcome
Identity is intact; the patient is still who they were before diagnosis; the question of "who will I be when MS takes more?" is still hypothetical — but it should be asked
Family dynamics: spouse/partner is still a partner, not yet a caregiver; the relationship has not yet been reshaped by illness

MOS–
1 YR

Phase 2: Transition to Progressive Disease

Secondary progression developing; EDSS climbing from 3.5 toward 6.0; this phase often lasts years — not months — and is marked by slow accumulation of disability rather than dramatic relapses
Patient requires a walking aid; driving becomes impossible; employment ends; the home is adapted; the relationship reshapes from partner to caregiver; cognitive changes begin subtly
DMT efficacy waning — relapses may be fewer but disability continues to accumulate; the neurologist may be escalating DMTs while the patient is wondering if any of it is working
This phase is the most psychologically productive window for palliative integration — the patient can still communicate, make decisions, and describe what matters most — yet it almost never receives palliative engagement
The losses in this phase are enormous: career, driving, sexual function, continence, some mobility — each one requires its own grief cycle; by the end of this phase, the patient has already grieved more than most hospice patients ever will

WKS–
MOS

Phase 3: Advanced Progressive MS — Hospice Enrollment Zone

EDSS 7.0–8.5; wheelchair or bed dependent; spasticity is the dominant symptom — painful involuntary spasms, continuous elevated tone, inability to be positioned comfortably; this is the paradigmatic MS hospice patient
Bladder managed with indwelling catheter or intermittent catheterization; bowel managed with scheduled protocol; pressure injury risk is highest; recurrent UTIs are expected; swallowing affected in some patients; speech affected in others
Cognitive changes significant in 40–70% — symbol digit modalities test (SDMT) reduced; processing speed slowed; memory affected; executive function impaired; the patient may understand everything but cannot communicate it clearly
Hospice enrollment is most appropriate at this phase; the patient who has been living with progressive MS for 20 years at EDSS 8.0–8.5 meets hospice criteria and deserves enrollment; the clinical team should assess heat sensitivity (Uhthoff phenomenon), spasticity adequacy, skin integrity, and bowel regularity at every visit
Family/caregiver has been doing this for years; caregiver burnout is likely; respite is not optional — it is a clinical safety intervention

DAYS–
WKS

Phase 4: Pre-Active Dying — EDSS 9.0–9.5

EDSS 9.0–9.5; completely dependent for all activities; minimal or no oral intake; communication limited to eye movement or facial expression in many patients; some patients are effectively locked in
Spasticity may plateau or paradoxically worsen; infections become more frequent and harder to treat; each UTI or aspiration pneumonia is a clinical crisis; comfort antibiotics may still be appropriate for symptom control
Comfort kit must be at bedside, confirmed, labeled, and reviewed with family: diazepam rectal gel or SQ, morphine SQ, midazolam SQ, glycopyrrolate SQ, acetaminophen rectal — have them drawn, not just prescribed
Do not stop baclofen — even at this stage; abrupt discontinuation causes seizures, hyperthermia, and a clinical emergency that is more distressing than the disease itself; if oral baclofen cannot be given, switch to diazepam SQ as a bridge and notify the neurologist immediately
Family teaching at this phase: what dying from MS looks like, what the final signs are, what family should do when they see them — say it out loud before it happens, not during

HRS–
DAYS

Phase 5: Final Hours

Cheyne-Stokes or agonal breathing; mandibular breathing; mottling of knees and feet ascending proximally; jaw relaxation; skin cools; peripheries become dusky; patient is unresponsive — but auditory awareness may persist longer than any other sense; continue speaking to the patient
Spasticity may paradoxically release in the final hours — muscles that have been rigid for years relax; this can be deeply disorienting for families who have watched years of spasms; tell them in advance: "As the body lets go, the spasms may stop — that is a form of peace"
Death in MS most commonly results from pneumonia, urosepsis, or pulmonary embolism — rarely from MS itself directly; the clinical team should prepare the family for this reality early: "The MS has made the body vulnerable; a pneumonia or infection will likely be what ends life — and when it comes, we will keep your loved one comfortable, not in the hospital"
Family instructions for final hours: call the hospice nurse — do not call 911; stay with the patient; speak softly; play meaningful music or read aloud; touch is appropriate and wanted; you do not need to do anything except be present; the nurse will come and guide you through what happens next
After-death care: allow the family time before the funeral home is called; the nurse will pronounce death; there is no rush; this person carried 25 years of illness to reach this moment — honor it

S10Clinician

Medications to Anticipate

Symptom-targeted pharmacology for this diagnosis. What to have in the comfort kit, what to titrate first, and what the evidence supports.

🚨 Spasticity: The Defining Medication Priority in MS Hospice

Spasticity management is the defining medication task in end-stage MS hospice and it is almost universally inadequate at enrollment. Spasticity causes severe intermittent pain from spontaneous spasms and continuous discomfort from elevated baseline muscle tone. It prevents comfortable positioning, driving pressure injury risk. It causes sleep fragmentation from nocturnal spasms. It impairs hygiene and catheter care. It is treatable to a degree that most enrolled patients have never experienced. The first medication question at every MS hospice enrollment is: Is the spasticity controlled? If the answer is no — and it almost always is — the next question is: why not, and what is the optimal regimen? Additionally: bladder management medication and bowel regimen are non-negotiable safety obligations, not optional symptom management. A patient with an impacted bowel or a blocked catheter is in medical crisis.^[44]

Drug	Class / Target Symptom	Starting Dose	Notes / Cautions
Baclofen Oral / via PEG	GABA-B agonist / Spasticity	5 mg TID → titrate to 10–20 mg TID–QID Max 80–100 mg/day	Foundational antispasticity agent in MS. Titrate from 5 mg TID upward every 3 days. Liquid formulation available for PEG tubes. ⚠ NEVER stop abruptly — baclofen withdrawal causes seizures, hyperthermia, and autonomic instability that can be fatal. Taper over days with diazepam cover if discontinuing. Most MS hospice patients at enrollment are undermedicated. EDSS 8.0 patient on 20 mg TID with 7/10 spasms has NOT been adequately treated.
Tizanidine	Alpha-2 agonist / Spasticity adjunct	2–4 mg TID → max 36 mg/day	Add to baclofen for inadequate spasticity control. Alpha-2 mechanism complements GABA-B pathway. ⚠ Sedation and orthostatic hypotension — use with caution if autonomic MS present. Liver function monitoring required (LFTs at baseline, 1 and 3 months).
Diazepam	Benzodiazepine (GABA-A) / Spasticity + Anxiety	2–10 mg TID (oral) 2–5 mg SQ q4–6h at end of life Rectal gel for emergencies	Particularly valuable for nocturnal spasms — give largest dose at bedtime. SQ diazepam available for end-of-life use. Essential emergency bridge for baclofen withdrawal — have rectal gel on hand always. Doubles as anxiolytic for spasm-related distress and anticipatory anxiety.
Dantrolene	Peripheral muscle relaxant / Spasticity	25 mg QD → titrate to 25–100 mg QID	Acts peripherally on ryanodine receptor — less CNS sedation than baclofen. Useful when central side effects limit baclofen titration. ⚠ Hepatotoxicity monitoring required — LFTs monthly. Avoid in liver disease. Muscle weakness as dose increases.^[45]
Gabapentin	Alpha-2-delta ligand / Neuropathic pain	100–300 mg TID → max 3,600 mg/day	First-line for MS neuropathic pain (burning, electric, dysesthetic). Start low, titrate slowly over 1–2 weeks. ⚠ Renal dose adjustment required — accumulates in renal impairment (common in MS with recurrent UTIs). Sedation additive with baclofen.^[33]
Pregabalin	Alpha-2-delta ligand / Neuropathic pain	75 mg BID → max 600 mg/day	Faster titration to therapeutic dose than gabapentin. Similar efficacy. Preferred when rapid pain control needed. Renal dose adjustment required. Schedule V — document therapeutic intent clearly.
Morphine	Opioid / Pain + Dyspnea	2.5–5 mg PO/SQ q4h ATC 1–2.5 mg SQ PRN q1h	Standard hospice opioid for pain and dyspnea. Titrate to effect — 25–50% increase if using ≥3 PRN doses/day. SQ route preferred when swallowing impaired. MS neuropathic pain may require higher opioid doses — do not underdose. ^[33]
Oxybutynin	Anticholinergic / Bladder spasm + Urgency	5 mg BID–TID Extended-release: 5–10 mg QD	Reduces bladder detrusor spasm in neurogenic bladder. ⚠ Anticholinergic burden — use with caution in patients with MS cognitive impairment (common). Worsens cognitive impairment. Consider mirabegron as alternative in cognitively affected patients.^[18]
Mirabegron	Beta-3 agonist / Bladder urgency + Incontinence	25–50 mg daily	Preferred over oxybutynin in patients with MS cognitive impairment — no anticholinergic CNS effects. Reduces urinary urgency and frequency. Well-tolerated. For patients with indwelling catheter, oxybutynin/mirabegron reduces bladder spasm around catheter tip.
Bisacodyl Suppository	Stimulant laxative / Bowel program	10 mg PR q48–72h SCHEDULED	Scheduled — NOT PRN. Core of neurogenic bowel program in MS. Given every 48 hours regardless of bowel movement in prior 48 hours. Impaction causes autonomic dysreflexia, pain, agitation, and spasm crisis. Document bowel output at every visit.^[19]
Docusate + Sennosides	Stool softener + Stimulant / Bowel maintenance	Docusate 100 mg BID + Senna 2 tabs BID	Maintenance bowel regimen between suppository doses. Docusate alone is insufficient — stimulant component is essential in neurogenic bowel. Do not use osmotic laxatives alone in immobile patients.
Mirtazapine	NaSSA antidepressant / Depression + Insomnia + Appetite	7.5–15 mg QHS	First-line antidepressant in MS hospice — addresses depression, insomnia (sedating at low doses), and anorexia simultaneously. Faster onset than SSRIs in this population. Do not increase above 15 mg if sedation is therapeutic. Paradoxically less sedating at higher doses.^[23]
Amantadine	Dopaminergic / MS Fatigue	100 mg BID (morning + noon)	Modest benefit for MS-specific neurological fatigue — distinct from systemic or cancer-related fatigue. Consider at EDSS <8.0 only. Avoid afternoon doses (insomnia). ⚠ Minimal benefit at EDSS 8.5–9.5 — discontinue if no benefit in 4 weeks.^[21]
Midazolam	Benzodiazepine / Terminal agitation + Crisis	2.5–5 mg SQ PRN q30min Draw and label at bedside	Terminal agitation, refractory spasm crisis, catastrophic symptom event. Must be drawn, labeled, and at bedside before the emergency — not prescribed to be obtained during it. Have 3 pre-drawn syringes in comfort kit at all times at EDSS 9.0+.
Glycopyrrolate	Anticholinergic / Terminal secretions	0.2 mg SQ q4h or 0.6–1.2 mg/24h CSCI	Preferred over hyoscine in conscious or semi-conscious patients — no CNS penetration means no sedation or confusion. Reduces pharyngeal and bronchial secretions (death rattle). Reposition to side-lying to facilitate drainage. Family education: the noise sounds worse than it feels.^[35]

🌿 MS Symptom Management Decision Tree

Evidence-based · Hospice-adapted · MS-specific

Select a symptom below to begin

What is the primary symptom or problem to address?

🚨 Comfort Kit Must-Haves for MS Hospice

Diazepam rectal gel (Diastat) OR Diazepam 5–10 mg SQ: Dual purpose — baclofen withdrawal emergency bridge AND acute spasticity crisis. Must be present before the emergency occurs. Educate family on how to give rectal gel.
Morphine SQ (2.5–5 mg pre-drawn): Pain crisis, dyspnea, and procedural pre-medication (wound care, catheter change). Three syringes labeled and in comfort kit at all times.
Midazolam SQ (2.5–5 mg pre-drawn): Terminal agitation, severe spasm crisis unresponsive to diazepam, refractory dyspnea. Draw and label before the crisis — not during it.
Glycopyrrolate SQ (0.2 mg pre-drawn): Terminal secretions. Pre-drawn and available at EDSS 9.0+. Preferred over hyoscine in patients who may still be aware.
Acetaminophen suppository (650 mg): Fever from UTI, pneumonia, or wound infection when oral route is unavailable. Comfort fever management — hospitalization for IV antibiotics is not consistent with comfort goals.

S11Clinician

Clinician Pointers

High-yield clinical pearls for the hospice team. The things not in the textbook — learned at the bedside over years of clinical experience.

Spasticity is almost always undertreated at enrollment — and you must change it today

Assess spasticity severity at every visit using Modified Ashworth Scale or a simple 0–10 patient rating for spasm frequency and severity. A patient rating spasms 7/10 on baclofen 20 mg TID has never been adequately treated — and that is the norm, not the exception. Titrate baclofen to effect without fear: doses up to 80–100 mg/day in divided doses are safe, effective, and supported by the evidence. Add tizanidine 4–8 mg TID as adjunct. Add diazepam 5–10 mg QHS for nocturnal spasms. Consider referral for intrathecal baclofen (ITB) pump evaluation — even in advanced MS, ITB placement transforms quality of life by eliminating painful spontaneous spasms that oral therapy cannot control. The patient who has been living with 7/10 spasms for three years because clinicians were afraid to titrate was let down by the system. Change it now.^[44]^[12]

Every sudden spasm increase is a signal — find the cause before adjusting medications

In MS, acute worsening of spasticity, agitation, or pain almost always indicates a new physical complication — not disease progression. Before adjusting any spasticity medication for an acute increase, perform a physical exam: check urinalysis and catheter patency, perform a skin assessment at all bony prominences, palpate for suprapubic fullness, and check for rectal impaction. The four culprits — UTI, blocked catheter, skin breakdown, and fecal impaction — are each reversible and each capable of producing a spasm crisis severe enough to be mistaken for terminal decompensation. The clinician who treats the spasm without looking for the cause has managed the symptom and missed the diagnosis. The complication is almost always treatable. Find it every time.^[44]

Pressure injury prevention is a clinical obligation documented and delegated at enrollment — not when breakdown occurs

A stage 3 or 4 pressure injury in an MS patient with spasticity is one of the most treatment-resistant, painful wounds in all of hospice. The combination of spasticity (which moves the patient across the wound surface with every spasm), immobility, incontinence, and neurological skin impairment makes healing profoundly difficult. Prevent this wound with the same urgency you would apply to preventing a cardiac event. Day one protocol: repositioning schedule every 2 hours (documented, delegated, and observed — not assumed), specialty alternating-pressure mattress (prescribed, not optional), moisture management with wicking incontinence products and barrier cream, protein 1.2–1.5 g/kg/day if oral intake allows, vitamin C and zinc supplementation, and daily skin inspection with family training on what to look for. Document this protocol in the care plan and check compliance at every visit.^[17]

UTI is the most common recurrent complication — recognize it in patients who cannot report it

In a patient with advanced MS and cognitive impairment, the classic UTI symptoms (dysuria, frequency) are masked. The presenting signs are: unexplained fever, sudden increase in spasticity or agitation, cloudy or foul-smelling urine, and confusion exceeding the baseline. Any of these in a catheterized MS patient is a UTI until proven otherwise. Obtain urinalysis and culture, treat per sensitivity. Change the catheter at the start of antibiotic treatment — biofilm on the catheter harbors bacteria and treatment-resistant organisms. For patients with ≥3 UTIs in 6 months, discuss prophylactic antibiotics (nitrofurantoin 50 mg QHS or trimethoprim 100 mg QHS) as a comfort intervention — the preventive benefit outweighs the resistance risk in this population.^[18]

The bowel program is non-negotiable — impaction causes spasm crisis, autonomic dysreflexia, and death in MS

Fecal impaction in an MS patient with neurogenic bowel is not a constipation problem — it is a spasticity emergency and autonomic crisis waiting to happen. Impaction causes severe spasm exacerbation, agitation, autonomic dysreflexia (hypertension, headache, sweating — a medical emergency in patients with high thoracic cord lesions), and pain that can drive a patient into the terminal phase prematurely. The bowel protocol is bisacodyl 10 mg PR every 48 hours, scheduled — not PRN. If the family says "she went yesterday," give the suppository anyway and document actual output. Check the rectal vault at every visit if bowel output is uncertain. Never discharge a MS hospice visit without confirming bowel status.^[19]

Baclofen withdrawal is a medical emergency — the family must understand this before it happens

Baclofen withdrawal is one of the most dangerous medication emergencies in MS hospice and one of the least anticipated by families. If oral baclofen is missed for 24–48 hours — because the patient cannot swallow, because the supply ran out, because someone forgot — the patient can develop seizures, hyperthermia exceeding 105°F, severe muscle rigidity, and altered consciousness. This is not a severe side effect — it is a medical emergency with a mortality rate. Teach the family before it happens: "Baclofen must be given on schedule, every dose, every day — it is as important as any other medication." Ensure the home always has diazepam rectal gel or SQ diazepam as an emergency bridge. For patients with ITB pumps, have a protocol for pump malfunction in writing. Never allow a hospice patient to be discharged with a baclofen prescription that is about to run out.^[13]

Cognitive impairment affects 40–70% of progressive MS — adjust communication, never assume absence of understanding

Cognitive impairment in progressive MS is common and underrecognized. It manifests primarily as slowed processing speed, working memory impairment, and reduced verbal fluency — not necessarily as dementia. The Symbol Digit Modalities Test (SDMT) is the most sensitive brief cognitive screen for MS. More critically: MS produces locked-in states in some patients. A patient who cannot speak, cannot move, and appears unresponsive may understand everything being said in the room. Always address the patient before family members, always explain what you are doing before doing it, always assume more comprehension than the clinical picture suggests, and use yes/no eye movement systems or picture boards as communication alternatives. The clinical team that talks about the patient in the third person while the patient lies in front of them is making an error of dignity that has no medical defense.^[20]

Racial disparities in MS are documented — the hospice team inherits them and has a responsibility to correct them

Black patients with MS have more aggressive disease, more rapid disability accumulation, later diagnosis, less access to high-efficacy DMTs, worse outcomes across all measured metrics, and higher rates of progressive disease from onset. These disparities are documented in the literature and exist independently of socioeconomic factors — they reflect systemic inequities in neurological care that have followed these patients their entire disease course. When a Black patient with MS arrives at hospice enrollment, they arrive carrying the weight of 20–30 years of suboptimal care. The hospice team that treats them identically to any other patient is missing the context. Assess for undertreated symptoms specifically — the evidence shows Black MS patients are more likely to have undertreated pain and spasticity at enrollment. Ask explicitly about prior care access, prior medication barriers, and current resource needs. Name the disparity. Address it directly.^[30]

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"The MS patient who arrives at hospice has been managing this disease longer than most of us have been in healthcare. They know what works, what doesn't, and what they need. The fastest way to lose their trust is to walk in like you're going to fix something they've been living with for 25 years. Ask first. Listen. Then optimize."

— Waldo, NP · Terminal2

S12EveryoneClinician

Psychosocial & Spiritual Care

Existential distress, depression screening, spiritual assessment, and goals-of-care communication. The symptom burden you can't see on a vitals sheet.

MS at end of life carries a psychosocial burden unlike any other hospice diagnosis because of the decades-long trajectory. By hospice enrollment, the patient has been grieving losses for 20 to 30 years — the loss of walking, driving, employment, continence, sexual function, hand coordination, speech clarity, and cognitive sharpness, each at its own time, each with its own grief cycle. They have not arrived at hospice with a single devastating loss. They have arrived after losing everything, one piece at a time, while remaining cognitively present for each loss.^[25]

The hospice clinician who acknowledges this history explicitly — who says out loud, "You have been adapting to losses for 25 years, and that is an extraordinary amount of grief to carry" — provides recognition that most clinical encounters over those 25 years never offered. That recognition is therapeutic. It is not sentiment. It is clinical care.

Psychological Distress Screening

Depression in MS — Prevalence 50% Lifetime

Grade B

Depression affects 50% of MS patients over the disease lifetime — higher than any other chronic neurological disease, and substantially higher than the general hospice population.^[32]

PHQ-2 screen at every enrollment: "Little interest or pleasure" + "Feeling down, depressed, or hopeless" — score ≥3 warrants full PHQ-9
The overlap problem: MS fatigue and depression produce nearly identical symptom profiles — differentiating requires asking about anhedonia, guilt, hopelessness, and passive death wish separately from fatigue severity
Mirtazapine 7.5 mg QHS: First-line antidepressant in MS hospice — simultaneously addresses depression, insomnia (critical in spasm-disrupted sleep), and anorexia; faster onset than SSRIs; minimal drug interactions
SSRIs (escitalopram 10 mg QD) are second-line; SNRIs (duloxetine) may have additional neuropathic pain benefit

Anxiety, Grief, and Decades of Serial Loss

Grade B

Anticipatory grief compounded by 25 years of serial losses: By hospice enrollment, the patient has completed multiple grief cycles — each lost function had its own period of denial, anger, bargaining, and adaptation; "grief fatigue" is real and clinically distinct from depression
Ask explicitly about prior losses: "What was the hardest thing MS took from you?" is both assessment and therapeutic — most patients have never been asked this directly
Distinguish grief from depression: Grief fluctuates; depression is pervasive. Both deserve attention; only one warrants pharmacotherapy in the first instance
Dignity Therapy (structured life narrative) reduces existential distress and increases sense of meaning — refer to social work for structured implementation^[24]
Lorazepam 0.5 mg PRN for acute anxiety episodes — avoid scheduled use unless breakthrough is frequent and distressing

Identity, Sexuality, and What Remains

MS progressively removes what people use to express who they are: physical capabilities, professional identity, sexual expression, social engagement, and finally — in some — the ability to communicate. By hospice enrollment, most of what defined this person in their own self-concept has been removed by the disease. What remains is the inner self — values, memories, preferences, relationships, humor, personality. The hospice clinician's job is to find that inner self and speak to it directly. The person who cannot move, cannot speak clearly, and cannot hold a glass was once someone who ran marathons, or built houses, or raised children, or wrote poetry. Those things still belong to them. Ask about them. Name them. They matter more than the clinical chart.

Sexuality and Intimacy in MS

Grade B

Sexual dysfunction affects over 80% of MS patients and is almost universally unaddressed in clinical care across the entire disease course.^[22]

Loss of genital sensation, spasticity-related positioning limitations, bladder urgency and catheter presence, profound fatigue, and progressive body image changes all impair sexual function and physical intimacy
Many couples with MS have restructured their intimate lives creatively over the decades — those strategies deserve acknowledgment, not silence
For couples where intimacy has been lost entirely, the grief about that loss deserves naming: "MS affects intimacy and sexuality for most people — is that something that has affected your relationship and that you'd like to talk about?"
Refer to social work or couples counseling when the patient/partner expresses this need; do not leave it on the table because it feels awkward

The Caregiver Who Was Once a Partner

Grade B

The spouse or partner of a patient with 25-year MS has watched their relationship transform from equal partners to caregiver and patient — often over so many gradual steps that there was no single moment of transition, just a slow accumulation of loss
Caregiver burden in MS is among the highest in all chronic disease — depression rates in MS caregivers approach 40%; burnout is the norm, not the exception^[31]
Respite care is not optional — it is a clinical safety intervention for a caregiver who has been providing full-time physical care, often for years
Screen the caregiver for depression at enrollment using PHQ-2; refer for counseling; offer couples therapy framing around "navigating the transition together" rather than "caregiver support"
The caregiver who cannot access respite will burn out — and burnout predicts worse patient comfort care and higher emergency utilization

Spiritual Assessment — FICA Framework Adapted for MS

Spirituality in long-trajectory diseases like MS is shaped differently than in cancer. The MS patient has had decades to construct meaning around their illness — and decades in which that meaning has been tested by each new loss. The FICA framework adapted for MS: Faith/beliefs — "What has given you strength over these 25 years? Has that changed as the disease has progressed?" Importance — "How important is your faith or spiritual life to you right now, at this stage?" Community — "Is there a faith community, a spiritual leader, or a group of people who have been part of your spiritual life and who should know where you are now?" Address — "What spiritual needs or questions feel unresolved for you?"

The spiritual question specific to MS that is rarely asked: "Was my life meaningful despite what MS took?" This is not a religious question. It is an existential accounting. The patient who can answer it with yes has made peace with the disease. The patient who cannot answer it — who is not yet sure whether the life lived alongside MS adds up to something — is in spiritual distress that requires active chaplaincy engagement, not just pastoral acknowledgment.

Legacy work takes on special urgency when cognitive impairment is present. A patient at EDSS 8.5 with early cognitive impairment can still participate in dignity therapy — life review, recorded narrative, legacy letters, recorded voice messages — but the window narrows. Refer to social work and chaplain at enrollment, not when the window closes.

Goals-of-Care Communication Specific to MS

The DMT Discontinuation Conversation

The patient who has been fighting MS with disease-modifying therapy for 20 years hears "stop your DMT" as "give up" — this framing is not just wrong, it is harmful
Reframe: "The medications you've been on have been fighting the inflammatory part of MS. At this stage, the inflammation is much less active — the disability comes from damage already done, not from new attacks. Stopping these medications doesn't change your disease — it removes a burden that no longer has a benefit."
Document the conversation: who was present, what was discussed, what was decided, and the clinical rationale
Coordinate with the neurologist — the hospice team should initiate this conversation but document neurologist involvement in the decision^[4]

The Permission to Stop Fighting

The patient who has been fighting for 25 years — who has tried every DMT, every clinical trial, every supplement, every therapy — may be exhausted but feel that stopping feels like betrayal of the fight
The most powerful clinical statement: "You have fought this disease every single day for 25 years. You have done everything anyone could have done. You don't have to fight anymore. You've earned the right to let us focus entirely on your comfort."
Distinguish "stopping treatment" from "shifting focus" — comfort-focused care is not cessation of care; it is redirection of care toward what matters now
Give permission explicitly — many patients wait for a clinician to say it is okay to stop; they cannot give themselves that permission after 25 years of fighting

Suicidal Ideation, Passive Death Wish, and MAID

Passive wish for death — "I'm ready to go," "I've had enough," "I wouldn't mind if I didn't wake up" — is common in MS hospice patients and must be understood in its full context. After 25 years of progressive loss, a passive death wish is often an existentially appropriate response to accumulated suffering, not a psychiatric emergency. It requires careful assessment to distinguish from active suicidal ideation.

Passive death wish: Common, often appropriate; deserves acknowledgment without panic or immediate psychiatric referral; explore the suffering driving it; address treatable contributors (pain, spasticity, depression); confirm presence of support.

Active suicidal ideation with plan or intent: Requires immediate psychiatric engagement; rare in MS hospice but occurs; document assessment and action clearly.

Medical aid in dying (MAID): Patients with progressive MS who have been fighting for decades may raise MAID in jurisdictions where it is legal. Know the law in your state or country. Do not dismiss the request — take it seriously as an expression of the patient's autonomy and their assessment of their own suffering. Even if the team cannot participate, the hospice clinician who engages respectfully and connects the patient with appropriate resources is providing care. The clinician who dismisses or deflects is not.^[24]

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"I sat with a woman once who had MS for 28 years. She couldn't move, couldn't speak clearly, needed help with everything. And she said to me — slowly, one word at a time — 'I used to run.' That's all she said. I didn't fill the silence. I just said, 'Tell me about that.' She spent 20 minutes telling me about running. And for 20 minutes, she wasn't a patient in a hospital bed. She was a runner. That's what we're here for — not just the spasms and the catheter and the pressure wound. That too. But also this."

— Waldo, NP · Terminal2

S13FamilyEveryone

Family Guide

Plain language for families. Share, print, or read aloud at the bedside.

You may have been caring for your loved one with MS for years — possibly for decades. You know this disease in ways that even clinical teams don't. The hospice team is here to support you both, to bring clinical expertise to the problems you've been managing alone, and to help carry some of the weight. This guide covers what you may see over the coming weeks, what you can do to help, and when to call us right away.

What You May See

Painful muscle spasms (spasticity): The legs or arms suddenly contract, extend, or jerk involuntarily and painfully. This is spasticity — one of the most treatable symptoms in MS. Give the scheduled baclofen or diazepam on time, every dose. Call the nurse if spasms are not controlled by medication or are suddenly much worse than usual.
Pressure sores: Red, darkened, or open areas of skin over bony areas (tailbone, heels, hips, shoulders). Even with excellent care, complete immobility creates pressure injury risk. Inspect the skin every time you turn your loved one. Call the nurse for any redness that does not blanch (turn white when you press it) or any open skin area.
Cloudy, dark, or foul-smelling urine: This often signals a urinary tract infection — the most common serious complication in MS with a catheter. Call the nurse the same day. Do not wait to see if it improves on its own.
Sudden increase in confusion, agitation, or spasms: In MS, sudden worsening almost always means something physical has changed — an infection, a blocked catheter, or a bowel impaction — not disease progression. Call the nurse before assuming it is just the disease getting worse. It usually has a treatable cause.
Profound fatigue: Resting after any minimal activity is expected and appropriate in advanced MS. Do not encourage pushing through fatigue — it makes everything worse. Energy conservation is a clinical strategy, not a failure.
Swallowing changes: Coughing or choking with liquids or solids, wet or gurgling voice quality after eating. Call the nurse — swallowing can be affected by MS, and the diet may need to be modified to prevent aspiration.

How You Can Help

Reposition every 2 hours — this is the most important thing you can do: Use the repositioning schedule your nurse provided. Always inspect the skin when you turn your loved one. Use the draw-sheet technique your nurse taught you. Set an alarm if needed. This single action prevents pressure wounds that could take months to heal.
Follow the bowel protocol exactly: The suppository every 48 hours is not optional — it must happen on schedule. If it doesn't happen, the bowel can become impacted and cause severe pain, agitation, and a crisis with the spasms. Document when the suppository was given and what the result was.
Empty the catheter bag regularly: Before the bag reaches full. A full, pulling catheter bag causes bladder spasm and discomfort. Check that the tubing is not kinked or bent. Report cloudy or foul-smelling urine immediately.
Give medications on time — especially baclofen: Baclofen must never be missed or stopped without talking to the nurse or doctor first. Missing doses can cause a dangerous withdrawal reaction. Set reminders. Keep a medication log.
Keep the room cool (68–72°F): Heat makes every MS symptom worse — spasms, fatigue, confusion, pain. A cool room is a medical intervention, not a preference. Use a fan, air conditioning, or cool compresses. A cooling vest can help during activities.
Talk to your loved one — they may understand everything: Even if your loved one cannot respond clearly, they may understand everything being said. Speak directly to them before speaking to others in the room. Read aloud, play their music, hold their hand, tell them what's happening. Presence and familiar voices are deeply comforting.

📞 Call the nurse immediately if you see:

• Sudden worsening of spasms that is not controlled by the scheduled medications
• New skin breakdown, open skin area, or redness that does not turn white when pressed
• Catheter not draining, leaking around the tube, or urine that becomes suddenly very cloudy or bloody
• Fever over 100.4°F (38°C)
• Sudden confusion, agitation, or unusual behavior beyond what is normal for your loved one
• Difficulty breathing, choking, or swallowing
• Signs of severe pain that are not relieved by the pain medication at home
• Any fall — even if your loved one seems uninjured
• If you feel you cannot safely care for your loved one or are overwhelmed — call us; you do not have to wait for a crisis

🙏 You have been on this journey for years — possibly decades. You have already shown extraordinary strength and love. The care you have provided has made an enormous difference. The hospice team is here to carry some of that weight now — to bring clinical expertise to the problems you've been managing alone, and to make sure your loved one's final chapter is as comfortable and peaceful as possible. You are not alone in this. Call us anytime. We mean it.

S14Everyone

Waldo's Top 10 Tips

Clinical field wisdom from 12+ years at the bedside. The things you learn after doing this long enough. Not guidelines — real.

01

Spasticity is undertreated at every single MS hospice enrollment — change it at the first visit. I have never met an MS patient at enrollment whose spasticity was adequately controlled. Not once. The typical patient arrives on baclofen 20 mg TID with spasm ratings of 7 or 8 out of 10. That is not failure of the disease — that is failure of titration. Baclofen goes to 80–100 mg/day in divided doses. Add tizanidine. Add diazepam for nighttime. If oral therapy is maxed out and spasms are still 7/10, refer for an intrathecal baclofen pump evaluation — even at EDSS 8.5, the pump changes everything. And if cannabis is legal where your patient lives, the evidence for MS spasticity is the strongest of any hospice indication. Use it. The patient who has been living with 7/10 spasms for three years because their clinicians were afraid to titrate has been let down. Fix it today.^[44]^[14]
02

Every sudden spasm increase is a clinical emergency requiring a physical exam — not a medication adjustment. When spasms suddenly worsen in an MS patient, the reflex is to increase the baclofen. Wrong. Check the catheter first — is it draining? Is it kinked? Is it blocked? Check the skin — is there new breakdown at a bony prominence? Palpate the abdomen — is the patient impacted? Send a urinalysis. Four things cause acute spasm exacerbation in MS: UTI, blocked catheter, fecal impaction, and skin breakdown. All four are treatable. All four, left untreated, will make the spasms worse regardless of what you do to the baclofen dose. Find the cause before you change the medication. The spasm is the body's only alarm system in a patient who cannot move or communicate clearly. Listen to it.^[44]
03

Pressure injury prevention is a clinical obligation — document it, delegate it, and enforce it at enrollment. A stage 3 or 4 pressure injury in an MS patient with spasticity is one of the most painful, most difficult-to-heal wounds in all of hospice. The spasticity shears the wound with every spasm. The immobility never allows full pressure relief. The incontinence keeps the wound moist. The neurological skin impairment slows healing. Once this wound exists, it will define the rest of this patient's hospice course — months of wound care, pain, infection risk, and suffering. Prevent it with the urgency of a cardiac arrest protocol: repositioning every 2 hours documented, specialty mattress prescribed on day one, moisture management in place, nutrition maximized, vitamin C and zinc added, daily skin inspection taught to family. Do not leave enrollment without every one of these in the care plan.^[17]
04

Baclofen withdrawal is a medical emergency and the family must know it before it happens — not during it. If oral baclofen is missed for 24–48 hours, this patient can develop seizures, hyperthermia, severe muscle rigidity, and altered consciousness that can be fatal. Missed doses happen. Swallowing becomes impossible. Supply runs out. A caregiver forgot. Every one of these has caused a baclofen withdrawal emergency in an MS hospice patient. Before it happens: teach the family — "Baclofen is as important as the heart medication. Never miss a dose. Never stop it without calling us." Ensure there is always diazepam rectal gel in the home as an emergency bridge. If the patient has an ITB pump, have a written malfunction protocol. Call the neurologist if the pump is approaching refill time. This is a preventable emergency — but only if you prevent it before it happens.^[12]^[13]
05

The DMT discontinuation conversation belongs at enrollment — not when the disease has progressed past the point of benefit. The neurologist who is ordering monthly MRIs and monthly infusions in a patient with EDSS 9.0 is monitoring without purpose and treating without benefit. Disease-modifying therapies reduce relapse frequency — but advanced progressive MS is not driven by relapses. The disability is already done. The monitoring burden (monthly labs, regular imaging, clinic visits) is entirely inconsistent with comfort goals. The conversation must happen at enrollment: "The medications you've been on have been fighting inflammation — but at this stage, the inflammation is much less active. Stopping these medications removes a burden without removing a benefit." Document it. Involve the neurologist. And give the patient explicit permission to stop fighting something that is no longer fighting the disease.^[4]
06

The bowel program is the most overlooked safety intervention in MS hospice — and impaction can kill. Every nurse I have trained in MS hospice has walked in thinking the bowel program is a comfort measure. It is a safety intervention. Fecal impaction in a patient with neurogenic MS bowel causes autonomic dysreflexia — a hypertensive crisis from uncontrolled sympathetic discharge below a high cord lesion — that can produce a stroke. It causes severe pain in a patient who cannot clearly report pain. It triggers a spasm crisis that looks exactly like disease progression. And it is entirely preventable with a scheduled bisacodyl suppository every 48 hours. Not PRN. Scheduled. Every 48 hours regardless of reported bowel status. Inspect the rectal vault at every visit if there is any doubt. Document actual bowel output. Never leave a visit without confirming bowel status in an MS hospice patient.^[19]
07

Cool the room — Uhthoff phenomenon means heat worsens every single MS symptom. Uhthoff phenomenon is the worsening of MS symptoms — including spasticity, fatigue, cognitive function, vision, and pain — in response to elevated body or ambient temperature. It is not a side effect. It is a physiological feature of demyelination: temperature-sensitive conduction in partially demyelinated axons. A room at 78°F will measurably worsen spasms, fatigue, and confusion in an MS patient compared to a room at 68°F. Keep the room at 68–72°F. Use a fan. Use a cooling vest for activities. Use cool compresses. This single intervention changes clinical visits — patients are calmer, spasms are less frequent, and cognitive function is clearer. Check the room temperature on every visit. It costs nothing and the evidence is solid.^[35]
08

Talk to the person, not the disease — cognitive impairment in MS does not mean the person is gone. MS produces locked-in states. It produces patients who cannot move, cannot speak intelligibly, and appear minimally responsive — but who understand everything being said in the room. The nurse who walks in and talks to the family about the patient while the patient lies in the bed is making an error of dignity. Always address the patient first. Explain what you are about to do before you do it. Use yes/no eye movements. Use picture boards. Use the patient's name. Ask about their history, their preferences, their comfort. Cognitive impairment in MS primarily affects processing speed and verbal fluency — comprehension may be much more intact than it appears. When in doubt, assume more comprehension than you see. The patient who feels unseen suffers more than the patient who feels heard.^[20]
09

The caregiver has been doing this for 20+ years — caregiver burden in MS is among the highest in all of chronic disease, and you must address it explicitly. The caregiver who answers "I'm fine" when you ask how they're doing has been saying "I'm fine" since the diagnosis 25 years ago. They have been providing full-time physical care — repositioning, catheter care, wound care, medication management, bowel protocols, emotional support — often while also managing a household, children, finances, and their own health. Depression in MS caregivers approaches 40%. Burnout predicts worse patient care outcomes and higher emergency utilization. Screen the caregiver for depression at enrollment. Offer respite — early and repeatedly, not once. Use caregiver-specific language: "Caring for someone with MS is one of the most demanding things a person can do. You have been doing this for decades. Tell me what you need." Say it. They won't ask on their own.^[31]
10

This person watched themselves disappear — every function lost, one at a time, over decades. They remember all of it. Say so. The MS patient at hospice has watched their own body become uninhabitable for 20 to 30 years. They remember the last time they walked. They remember the day they stopped driving. They remember when they couldn't hold a pen. They remember when their voice changed. They carry all of that. The hospice clinician who acknowledges this history explicitly — who says, out loud, "You have carried an extraordinary amount for an extraordinarily long time" — provides something that almost no clinical encounter in their entire disease history has provided: recognition. Not problem-solving. Not medication adjustment. Recognition. That is clinical care. It is the best clinical care you can provide on that day. Say it out loud. Don't wait for the right moment — every visit is the right moment.^[25]

— Waldo, NP

REFClinician

References

Peer-reviewed citations. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.

Wallin MT, Culpepper WJ, Campbell JD, et al. The prevalence of MS in the United States: A population-based estimate using health claims data. Neurology. 2019;92(10):e1029–e1040.

PMID 30770430Observational

Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–173.

PMID 29275977Guideline

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–1452.

PMID 6685237Observational

Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–286.

PMID 24871874Guideline

Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(Pt 3):606–616.

PMID 16415308Review

Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296–301.

PMID 35025605Observational

Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol. 2007;61(4):288–299.

PMID 17444504Review

Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004;62(1):60–65.

PMID 14718698Observational

Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis (ORATORIO trial). N Engl J Med. 2017;376(3):209–220.

PMID 28002688RCT

Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND trial). Lancet. 2018;391(10127):1263–1273.

PMID 29576505RCT

Kister I, Spelman T, Alroughani R, et al. Discontinuing disease-modifying therapy in MS after prolonged relapse-free period: a propensity score-matched study. J Neurol Neurosurg Psychiatry. 2016;87(10):1133–1137.

PMID 27221333Observational

Penn RD, Savoy SM, Corcos D, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med. 1989;320(23):1517–1521.

PMID 2657424RCT

Coffey RJ, Edgar TS, Francisco GE, et al. Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil. 2002;83(6):735–741.

PMID 12048649Observational

Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex) as add-on therapy in subjects with refractory spasticity caused by multiple sclerosis (MOVE 2 trial). Eur J Neurol. 2011;18(9):1122–1131.

PMID 21362108RCT

Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007;14(3):290–296.

PMID 17355549RCT

Simpson DM, Alexander DN, O'Brien CF, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review). Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1691–1698.

PMID 18458229Systematic Review

National Pressure Injury Advisory Panel (NPIAP), European Pressure Ulcer Advisory Panel, Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers/Injuries: Clinical Practice Guideline. The International Guideline. NPIAP / EPUAP / PPPIA. 2019.

npiap.com/guidelinesGuideline

Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009;80(5):470–477.

PMID 19372287Guideline

Preziosi G, Gordon-Dixon A, Emmanuel A. Neurogenic bowel dysfunction in patients with multiple sclerosis: prevalence, impact, and management strategies. Degener Neurol Neuromuscul Dis. 2018;8:79–90.

PMID 30588126Review

Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008;7(12):1139–1151.

PMID 19007738Review

Krupp LB, Serafin DJ, Anand R. Multiple sclerosis-associated fatigue: definition, pathophysiology, assessment, and treatment. CNS Drugs. 2008;22(6):489–508.

PMID 18484791Review

Lew-Starowicz M, Rola R. Prevalence of sexual dysfunctions among women with multiple sclerosis. Sex Disabil. 2013;31(2):141–153.

DOI 10.1007/s11195-013-9293-9Review

Buchanan RJ, Wang S, Tai-Seale M, Ju H. Analyses of nursing home residents with multiple sclerosis and depression using the Minimum Data Set. Mult Scler. 2010;16(2):164–171.

PMID 20028706Observational

Golla H, Galushko M, Pfaff H, Voltz R. Multiple sclerosis and palliative care — perceptions of severely affected multiple sclerosis patients and their health professionals: a qualitative study. BMC Palliat Care. 2014;13:11.

PMID 24618351Qualitative

Kister I, Chamot E, Salter AR, Cutter GR, Bacon TE, Herbert J. Disability in multiple sclerosis: a reference for patients and clinicians. Neurology. 2013;80(11):1018–1024.

PMID 23403165Observational

Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial (ENHANCE). Lancet. 2009;373(9665):732–738.

PMID 19249634RCT

Cree BAC, Gourraud PA, Oksenberg JR, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016;80(4):499–510.

PMID 27464262Observational

Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. 2010;74(13):1041–1047.

PMID 20350978Observational

Hirst C, Swingler R, Compston DAS, Ben-Shlomo Y, Robertson NP. Survival and cause of death in multiple sclerosis: a prospective population-based study. J Neurol Neurosurg Psychiatry. 2008;79(9):1016–1021.

PMID 18303107Observational

Langer-Gould A, Brara SM, Beaber BE, Koebnick C. Incidence of multiple sclerosis in multiple racial and ethnic groups. Neurology. 2013;80(19):1734–1739.

PMID 23596071Observational

Minden SL, Frankel D, Hadden L, Perloff J, Srinath KP, Hoaglin DC. The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics. Mult Scler. 2006;12(1):24–38.

PMID 16459717Observational

Amato MP, Ponziani G, Rossi F, Liedl CL, Stefanile C, Rossi L. Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. Mult Scler. 2001;7(5):340–344.

PMID 11724451Observational

Solaro C, Brichetto G, Amato MP, et al. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology. 2004;63(5):919–921.

PMID 15365149Observational

Ehde DM, Gibbons LE, Chwastiak L, Bombardier CH, Sullivan MD, Kraft GH. Chronic pain in a large community sample of persons with multiple sclerosis. Mult Scler. 2003;9(6):605–611.

PMID 14664474Observational

Crayton HJ, Rossman HS. Managing the symptoms of multiple sclerosis: a multimodal approach. Clin Ther. 2006;28(4):445–460.

PMID 16750459Review

Rommer PS, Zettl UK, Kieseier B, et al. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. JAMA Neurol. 2016;73(12):1390–1398.

PMID 27802505Review

Belbasis L, Bellou V, Evangelou E, Ioannidis JP, Tzoulaki I. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol. 2015;14(3):263–273.

PMID 25662901Meta-analysis

Coyle PK. Symptom management and lifestyle modifications in multiple sclerosis. Continuum (Minneap Minn). 2016;22(3):815–836.

PMID 27261684Review

Veauthier C, Paul F. Sleep disorders in multiple sclerosis and their relationship to fatigue. Sleep Med. 2014;15(1):5–14.

PMID 24360534Review

Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology. 2018;90(17):777–788.

PMID 29686116Guideline

Chataway J, De Angelis F, Connick P, et al. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. Lancet Neurol. 2020;19(6):470–480.

PMID 32353267RCT

Ben-Zacharia AB. Therapeutics for multiple sclerosis symptoms. Mt Sinai J Med. 2011;78(2):176–191.

PMID 21425263Review

Ontaneda D, Thompson AJ, Fox RJ, Cohen JA. Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Lancet. 2017;389(10076):1357–1366.

PMID 27889191Review

Haselkorn JK, Balsdon Richer C, Fry Welch D, et al. Overview of spasticity management in multiple sclerosis. Evidence-based management strategies for spasticity treatment in multiple sclerosis. J Spinal Cord Med. 2005;28(2):167–199.

PMID 16048146Review

Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev. 2003;(4):CD001332.

PMID 14583932Systematic Review

terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed and authoritative clinical guidelines. © Terminal2 | terminal2.care

📝

Private Notes

Session notes — not saved to any server. Clears when you close the tab.

Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.